Skip to main content
ConductScienceScienceDex

Matthew W Kalnik

NIH Rank #1036
Unclaimed recordClaim profile
  • Program Leader
  • Top 10% Funded
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 12056766Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2024

Linked Award Amount
$5.2M
Full award amounts, FY2024
Award Records
1
Records listing this PI
Award-Linked Rank
#1,036
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Matthew W Kalnik. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Matthew W Kalnik as a PI. Multi-PI records show the full award amount for context.

  • 5U01DA058547-02U01
    IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody
    Antidote Therapeutics, Inc.
    $5.2M
    award amount

Award organization

Organizations that administered FY2024 awards listing Matthew W Kalnik as a PI.

FY2024 award administered by Antidote Therapeutics, Inc. (MD).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Antidote Therapeutics, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #1036
  7. 2024
    Entered Top 25% Nationally
    Ranked #1036
  8. 2024
    Entered Top 10% Nationally
    Ranked #1036

Explore further

Find collaborators for Matthew W Kalnik

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →